drugset / Trial / NCT01709071

Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

NCT01709071

Phase 1/2 Completed 140 enrolled Pauline Verdijk World Health Organization · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A new inactivated polio vaccine based on attenuated poliovirus strains was developed to transfer the technology to manufacturers in low- and middle-income countries. This vaccine was produced in different dosages and in different formulations. In healthy adults the safety of the highest dose was comparable to that of the existing inactivated polio vaccine. The purpose of this trial is to determine the safety of the different dosages and formulations of the vaccine in infants. The second goal of this study is to analyse the immune response after three doses in infants.

Timeline

Start
2012-02
Primary completion
2012-11
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Adjuvanted Sabin-IPV Unknown 0.5 ml Intramuscular
Comparator IPV Vaccine 0.5 ml Intramuscular
Subject Sabin-IPV Vaccine 0.5 ml Intramuscular

Indications